NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Exogene

Exogene

Private
OxfordHealthcare & Life Scienceshttps://exogene.co.uk/

Last Round

Grant

Oct 15, 2025

Total Funding Raised

$5.55M

Company Overview

Exogene is a biotechnology company that utilizes an artificial intelligence platform for the discovery and development of T-cell receptor (TCR)-based cell therapies for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

T-cell receptor discoveryTCR discoveryprotein engineeringcancer immunotherapygenerative AIdrug discoverytechbiobiophysical simulationhigh-throughput screeninglab-in-the-loopcell therapyTCR affinity enhancementcomputational drug discoveryoncologyAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exogene Comparables

Compare Exogene with similar companies based on industry and business-model similarity.

Exogene comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synteny
93%
Etcembly
91%
ImmunoScape
77%

Exogene Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 15, 2025
Convertible DebtOct 10, 2025
SeedApr 28, 2022

Key People

Founding team and executive leadership

Andrea Mambrini

CTO Co-Founder

Founding Team

Federico Paoletti

CEO Co-Founder

Founding Team

Exogene Investors

Notable investors and investment history

Exogene investors
InvestorRounds
KQ LabsSeed
Selvedge VentureSeed
R42 GroupSeed
Entrepreneurs FirstSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 1, 2025

    Added Immunocore Ltd, a mid-market biotechnology company, as a customer.

Exogene Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Exogene Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Exogene's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range15
Year Founded2019
Last FundingOct 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.